Twist Bioscience

TWST

$
49.64
(
1.2
%)
(
+
1.2
%)
+
-42.0
%
28.77
NASDAQ

Last Price

02/11/26, 09:30 AM
 EDT

Margin of Safety

Current Compounder
$
28.77

PORTFOLIO CATEGORY

Modeled fair value

Up to 5%
$1.896 billion

Allocation Suggestion

Modeled fair value

Model Basis

LAST REFINED:
February 10, 2026
The current model INCLUDES the following assets and assumptions:
The current model is based on operating metrics, including:
  • Component A: Full-year 2026 revenue of $448.190 million, representing an 18.7% increase from the prior year (+$70.626 million)
  • *Twist Bioscience's fiscal year begins on October 1
The current model EXCLUDES the following assets:
  • Licensing deals for antibody drug candidates discovered with Twist's technology platform
  • DNA data storage initiatives (deprioritized by the business)

Research Deep Dive

Last Updated:

Overview

Solt DB Invest will introduce Base Research for our coverage ecosystem over the next month to coincide with third-quarter 2023 earnings announcements. Check back soon!

Technology Platform

Pipeline

Portfolio

Opportunities & Advantages

Challenges & Risks

Development Risk 

Regulatory Risk 

Commercial Risk 

Dilution Risk 

Valuation Risk 

Geopolitical Risk 

Unique Risks 

Modeling Insights

News Flow & Timing

SEC Filings